Vinay Mathew Thomas
@vinay_onc
Followers
515
Following
1K
Media
37
Statuses
941
Husband | Girl Dad | GU Oncology @Huntsman_GU | Prior Heme/onc fellow @huntsmancancer | Prior Chief Medical Resident and Internal Medicine Resident @UConnIM
Joined July 2017
(1/4) Here’s a tweetorial for LenCabo now available in @Annals_Oncology, https://t.co/qDJrPsv9yD This was a multicenter, phase 2 trial that randomized 90 patients with mccRCC and is the 1st head-to-head comparison of contemporary angiogenesis TT after PD-1 CPI
3
25
62
Beyond thrilled to have matched @MDAndersonNews for Hematology/Oncology fellowship!!! Immensely grateful to my mentor @neerajaiims, @Huntsman_GU, and all the incredible mentors who made this possible: @umangtalking @TiansterZhang @littlejonesmd @HHammersMD @OncHahn #Match2025
22
15
208
Super supportive! He has been an outstanding mentor and sponsor to so many and would do a fantastic job on the ASCO Nominating Committee. He absolutely deserves it. Please vote for him!
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
1
3
10
💥 New in @JAMAOnc: long-term physical activity & digestive system cancer (DSC) risk https://t.co/gSjQVyUkIX 🎯 ≥45 vs <3 MET-h/week → lower DSC incidence (HR 0.83) & mortality (HR 0.72) ▪️Best protection at ~50 MET-h/week ▪️Consistency matters: ~17 MET-h/week sustained over
1
14
28
1/5 Just out 👉@NatRevClinOncol "Biomarkers in UC". HER2, FGFR3, PD-L1 are approved and ctDNA is becoming a reality. We address methodological inconsistencies, need for standardization & AI integration 🔗Open access – https://t.co/15VURJXPiu
@OncoAlert @tompowles1 @b_szabados
7
38
65
One more step towards Personalised Medicine in Prostate Cancer (mHSPC): CAPITELLO 281 study (TMH Varanasi, India was an enrolling centre) PTEN deficient mHSPC: Significant improvements with addition of Capivasertib Toxicities present, but manageable. @neerajaiims @montypal
2
4
12
1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: https://t.co/q1UwZr8L3i
#endRMC #MsaouelLab @MDAndersonNews
15
61
164
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. https://t.co/0vqWHuJ9tm
3
31
91
Terrific job by @sola_sesola2003 & team @NatRevUrol 👉PSMA-targeting therapies in #prostatecancer 👉molecular imaging & radionuclide Rx reshaping management strategies for advanced disease👉 https://t.co/jqYx3l6eIE Teaser👇@OncoAlert @urotoday @PCF_Science @DrMHofman #GaryCook
1
26
39
0
3
8
This is the most effective therapy we have developed to date for #RenalMedullaryCarcinoma contributing greatly to the recent doubling of median survival for this disease. Still much work to be done to #EndRMC and all rare &common #kidneycancer subtypes but the momentum is strong!
⭐ #IKCSNA25 HIGHLIGHT Panitumumab+nab-paclitaxel is reshaping care for heavily pretreated #RenalMedullaryCarcinoma. ORR 53.9% (CR 15.4%). @PavlosMsaouel @MDAndersonNews bringing hope & accelerating research for #RareKidneyCancers. #MsaouelLab #endRMC
1
14
48
Delighted to see @neerajaiims on the @ASCO Nominating Committee ballot! An amazing human being who's mentored countless young trainees to faculty positions & a quintessential mentor uplifting everyone around him. His contributions as Editor-in-Chief of ASCO Daily News have been
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
2
16
58
Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.
1
12
26
Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert
0
12
17
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
19
100
234
Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?
4
45
146
🚨🧬 Hot off the press! Pleased to share our commentary in @ASCO Journal of Clinical Oncology @JCO_ASCO in the Comments & Controversies section👉 "Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review" @Dr_R_Kurzrock @ASCOPost 👉Why
0
10
30
Important for all clinicians to ask individuals about their use of supplements & discuss w/individuals living w/cancer Biotin Supplements for Hair and Nail Regrowth: A Caution for Oncologists | @JCO_ASCO @oncologynursing @OncoAlert
https://t.co/AF7YF1zxZY
ascopubs.org
1
7
7
These findings add to the increasing evidence that cancer is not driven solely by DNA mutations. 🧵
11
109
584
Excellently reviewed by Neeraj Agarwal at #IUCS25. From therapeutic targets to PARP combos and Lu-177 trials, a clear map of progress in advanced prostate cancer. @urologysummit @gbanna74 @ravikanesvaran @OncoAlert @ONCOassist @neerajaiims @PGrivasMDPhD @drenriquegrande
0
15
34